Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/10422
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNikolic V.-
dc.contributor.authorJankovic, Slobodan-
dc.contributor.authorVeličković-Radovanović R.-
dc.contributor.authorApostolovic, Svetlana-
dc.contributor.authorStanojevic D.-
dc.contributor.authorŽivanović, Slavoljub-
dc.contributor.authorStefanović, Nikola-
dc.contributor.authorPesic, Srdjan-
dc.contributor.authorJevtovic Stoimenov, Tatjana-
dc.contributor.authorDjuric, Janko-
dc.contributor.authorGrbovic-Markovic V.-
dc.contributor.authorMilovanovic, Jasmina-
dc.date.accessioned2021-04-20T15:42:29Z-
dc.date.available2021-04-20T15:42:29Z-
dc.date.issued2013-01-01-
dc.identifier.issn00223549-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/10422-
dc.description.abstractThe aim of this study was to derive population pharmacokinetic (PK) model for clearance (CL) of carvedilol in adult patients with chronic heart failure (CHF). Medication and demographic data were obtained from 52 Caucasian patients with CHF taking carvedilol. Population PK analysis was performed by nonlinear mixed-effects modeling (NONMEM) to estimate and identify different factors that could affect carvedilol CL. A total of 55 plasma concentrations were collected from 52 patients with mean age of 63.02± 11.95 years and total body weight (TBW) of 77.96± 13.46 kg. Total daily doses of carvedilol in the target population had wide range of variability (6.25-50 mg), followed by high variability of drug plasma concentrations (1-59.07 ng/mL). The typical mean value for carvedilol CL, estimated by the base model, in the target population was 43.8 L/h. The TBW, concomitant therapy with digoxin, and tobacco using were determinants of a derived population model. The final regression model for the CL of carvedilol is: CL(L/h) = 10 + 0.434 TBW + 22.5 Digoxin + 29.9 Tobacco Our results suggest that the TBW, concomitant therapy with digoxin, and tobacco using are the main subjects of carvedilol PK variability. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.-
dc.relation.ispartofJournal of Pharmaceutical Sciences-
dc.titlePopulation pharmacokinetics of carvedilol in patients with congestive heart failure-
dc.typeArticle-
dc.identifier.doi10.1002/jps.23626-
dc.identifier.scopus84881029832-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

[ Google Scholar ]

Page views(s)

20

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open Request a copy


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.